Emergent Payout Ratio vs Capex To Operating Cash Flow Analysis

EBS Stock

USD 10.27 0.07 0.68%

Emergent Biosolutions financial indicator trend analysis is much more than just examining Emergent Biosolutions latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Emergent Biosolutions is a good investment. Please check the relationship between Emergent Biosolutions Payout Ratio and its Capex To Operating Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Payout Ratio vs Capex To Operating Cash Flow

Payout Ratio vs Capex To Operating Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Emergent Biosolutions Payout Ratio account and Capex To Operating Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between Emergent Biosolutions' Payout Ratio and Capex To Operating Cash Flow is 0.08. Overlapping area represents the amount of variation of Payout Ratio that can explain the historical movement of Capex To Operating Cash Flow in the same time period over historical financial statements of Emergent Biosolutions, assuming nothing else is changed. The correlation between historical values of Emergent Biosolutions' Payout Ratio and Capex To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payout Ratio of Emergent Biosolutions are associated (or correlated) with its Capex To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Operating Cash Flow has no effect on the direction of Payout Ratio i.e., Emergent Biosolutions' Payout Ratio and Capex To Operating Cash Flow go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Payout Ratio

Payout Ratio is the proportion of Emergent Biosolutions earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Emergent Biosolutions dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Emergent Biosolutions is paying out more in dividends than it makes in net income.

Capex To Operating Cash Flow

Most indicators from Emergent Biosolutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Emergent Biosolutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.At this time, Emergent Biosolutions' Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.32 in 2025, whereas Discontinued Operations is likely to drop (13 M) in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	593.2M	1.1B	484.1M	294.2M
Cost Of Revenue	693.7M	689.3M	668.2M	701.6M

Total Operating Expenses Cost Of Revenue

Emergent Biosolutions fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.93	0.59	0.62	0.94	0.72	0.66	0.45	0.6	0.73	0.74	0.54	0.03	0.73	0.62	0.63	0.75	0.57	0.62	0.79	0.86	0.96	0.64	0.48	0.69	0.64
Short Long Term Debt Total	0.93		0.62	0.77	0.75	0.67	0.83	0.29	0.62	0.59	0.76	0.69	0.09	0.59	0.56	0.72	0.65	0.59	0.71	0.76	0.8	0.99	0.63	0.65	0.77	0.75
Other Current Liab	0.59	0.62		0.63	0.44	0.84	0.49	0.59	0.96	0.43	0.89	0.73	-0.59	0.43	0.74	0.84	0.07	0.84	0.83	0.88	0.36	0.66	0.94	0.3	0.82	0.83
Total Current Liabilities	0.62	0.77	0.63		0.44	0.71	0.61	0.38	0.62	0.51	0.69	0.9	-0.08	0.51	0.31	0.52	0.18	0.34	0.67	0.67	0.38	0.7	0.69	0.93	0.61	0.57
Total Stockholder Equity	0.94	0.75	0.44	0.44		0.68	0.4	0.54	0.45	0.81	0.59	0.33	0.01	0.81	0.53	0.41	0.75	0.41	0.43	0.7	0.79	0.81	0.55	0.33	0.48	0.42
Property Plant And Equipment Net	0.72	0.67	0.84	0.71	0.68		0.42	0.8	0.83	0.63	0.92	0.67	-0.52	0.63	0.74	0.69	0.21	0.7	0.71	0.82	0.41	0.7	0.94	0.47	0.75	0.67
Net Debt	0.66	0.83	0.49	0.61	0.4	0.42		-0.13	0.51	0.09	0.65	0.57	0.15	0.08	0.54	0.76	0.46	0.58	0.75	0.49	0.67	0.81	0.39	0.48	0.8	0.77
Retained Earnings	0.45	0.29	0.59	0.38	0.54	0.8	-0.13		0.59	0.66	0.63	0.38	-0.58	0.66	0.5	0.3	-0.02	0.45	0.21	0.57	0.08	0.34	0.73	0.22	0.37	0.26
Accounts Payable	0.6	0.62	0.96	0.62	0.45	0.83	0.51	0.59		0.37	0.91	0.78	-0.54	0.37	0.81	0.86	0.09	0.85	0.83	0.87	0.4	0.66	0.91	0.3	0.85	0.83
Cash	0.73	0.59	0.43	0.51	0.81	0.63	0.09	0.66	0.37		0.42	0.37	-0.06	1.0	0.19	0.16	0.49	0.2	0.27	0.7	0.45	0.61	0.59	0.45	0.21	0.18
Non Current Assets Total	0.74	0.76	0.89	0.69	0.59	0.92	0.65	0.63	0.91	0.42		0.73	-0.4	0.42	0.84	0.9	0.22	0.88	0.8	0.8	0.5	0.79	0.89	0.42	0.95	0.86
Non Currrent Assets Other	0.54	0.69	0.73	0.9	0.33	0.67	0.57	0.38	0.78	0.37	0.73		-0.15	0.37	0.44	0.63	0.09	0.47	0.69	0.7	0.36	0.65	0.71	0.76	0.67	0.66
Other Assets	0.03	0.09	-0.59	-0.08	0.01	-0.52	0.15	-0.58	-0.54	-0.06	-0.4	-0.15		-0.06	-0.47	-0.33	0.39	-0.46	-0.36	-0.37	0.24	0.05	-0.59	0.16	-0.29	-0.31
Cash And Short Term Investments	0.73	0.59	0.43	0.51	0.81	0.63	0.08	0.66	0.37	1.0	0.42	0.37	-0.06		0.19	0.16	0.49	0.2	0.27	0.7	0.44	0.61	0.59	0.45	0.21	0.18
Net Receivables	0.62	0.56	0.74	0.31	0.53	0.74	0.54	0.5	0.81	0.19	0.84	0.44	-0.47	0.19		0.85	0.31	0.89	0.69	0.63	0.54	0.64	0.72	0.02	0.84	0.81
Good Will	0.63	0.72	0.84	0.52	0.41	0.69	0.76	0.3	0.86	0.16	0.9	0.63	-0.33	0.16	0.85		0.26	0.94	0.87	0.72	0.57	0.74	0.76	0.23	0.97	0.98
Common Stock Shares Outstanding	0.75	0.65	0.07	0.18	0.75	0.21	0.46	-0.02	0.09	0.49	0.22	0.09	0.39	0.49	0.31	0.26		0.2	0.28	0.4	0.9	0.69	0.14	0.18	0.25	0.31
Non Current Liabilities Total	0.57	0.59	0.84	0.34	0.41	0.7	0.58	0.45	0.85	0.2	0.88	0.47	-0.46	0.2	0.89	0.94	0.2		0.73	0.69	0.45	0.65	0.76	0.01	0.91	0.88
Inventory	0.62	0.71	0.83	0.67	0.43	0.71	0.75	0.21	0.83	0.27	0.8	0.69	-0.36	0.27	0.69	0.87	0.28	0.73		0.8	0.56	0.71	0.8	0.4	0.84	0.89
Other Current Assets	0.79	0.76	0.88	0.67	0.7	0.82	0.49	0.57	0.87	0.7	0.8	0.7	-0.37	0.7	0.63	0.72	0.4	0.69	0.8		0.59	0.79	0.89	0.42	0.72	0.73
Other Stockholder Equity	0.86	0.8	0.36	0.38	0.79	0.41	0.67	0.08	0.4	0.45	0.5	0.36	0.24	0.44	0.54	0.57	0.9	0.45	0.56	0.59		0.84	0.36	0.29	0.57	0.63
Total Liab	0.96	0.99	0.66	0.7	0.81	0.7	0.81	0.34	0.66	0.61	0.79	0.65	0.05	0.61	0.64	0.74	0.69	0.65	0.71	0.79	0.84		0.65	0.55	0.79	0.77
Total Current Assets	0.64	0.63	0.94	0.69	0.55	0.94	0.39	0.73	0.91	0.59	0.89	0.71	-0.59	0.59	0.72	0.76	0.14	0.76	0.8	0.89	0.36	0.65		0.41	0.75	0.74
Short Term Debt	0.48	0.65	0.3	0.93	0.33	0.47	0.48	0.22	0.3	0.45	0.42	0.76	0.16	0.45	0.02	0.23	0.18	0.01	0.4	0.42	0.29	0.55	0.41		0.34	0.31
Intangible Assets	0.69	0.77	0.82	0.61	0.48	0.75	0.8	0.37	0.85	0.21	0.95	0.67	-0.29	0.21	0.84	0.97	0.25	0.91	0.84	0.72	0.57	0.79	0.75	0.34		0.94
Common Stock	0.64	0.75	0.83	0.57	0.42	0.67	0.77	0.26	0.83	0.18	0.86	0.66	-0.31	0.18	0.81	0.98	0.31	0.88	0.89	0.73	0.63	0.77	0.74	0.31	0.94

Click cells to compare fundamentals

Emergent Biosolutions Account Relationship Matchups

Emergent Biosolutions fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	2.9B	3.0B	3.2B	1.8B	1.4B	1.2B
Short Long Term Debt Total	874.8M	841M	1.4B	860.2M	676.1M	383.8M
Total Stockholder Equity	1.4B	1.6B	1.4B	649.3M	482.8M	618.0M
Net Debt	253.5M	264.9M	763.2M	748.5M	576.6M	605.4M
Cash	621.3M	576.1M	642.6M	111.7M	99.5M	94.5M
Cash And Short Term Investments	621.3M	576.1M	642.6M	111.7M	99.5M	94.5M
Common Stock Shares Outstanding	53.8M	54.1M	50.1M	51.2M	53M	42.1M
Liabilities And Stockholders Equity	2.9B	3.0B	3.2B	1.8B	1.4B	1.2B
Other Current Assets	73.2M	70.4M	57.9M	47.9M	33M	26.8M
Other Stockholder Equity	745.3M	677.2M	645.8M	676.7M	700.3M	366.1M
Total Liab	1.4B	1.3B	1.8B	1.2B	906.9M	549.1M
Other Liab	199.9M	210.7M	156.8M	90.4M	104.0M	66.7M
Current Deferred Revenue	101.9M	131.5M	140.4M	26.4M	30.4M	28.1M
Long Term Debt	841M	809.4M	448.5M	446.5M	663.7M	696.9M
Property Plant And Equipment Gross	644.1M	800.1M	817.6M	794.2M	667.7M	396.8M
Accumulated Other Comprehensive Income	(25.3M)	(16.1M)	3.1M	(5.7M)	(5.2M)	(5.5M)
Property Plant Equipment	644.1M	800.1M	817.6M	399M	282.3M	356.0M
Retained Earnings Total Equity	421.8M	726.9M	957.8M	734M	844.1M	440.2M
Deferred Long Term Liab	63.9M	53.2M	94.9M	71.8M	82.6M	86.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC